PMID: 6983831Nov 1, 1982Paper

The treatment of acute myelocytic leukemia in patients 30 years of age and younger

American Journal of Hematology
H PreislerA Freeman

Abstract

The treatment of acute myelocytic leukemia in childhood and young adults has lagged behind that for acute lymphocytic leukemia. The studies described here were directed towards evaluating the role of intensive chemotherapy in the treatment of this illness. Intensive remission induction therapy combining cytosine arabinoside with an anthracycline antibiotic produced a complete remission rate comparable to that achieved in acute lymphocytic leukemia (45 of 49 patients or 92%). Intensive consolidation chemotherapy produced a median duration of complete remission of 160 weeks with 40% of patients projected to be in remission at 4 years. By contrast, the median duration of remission for patients treated with moderate consolidation/maintenance therapy was 23 weeks with only 10% of patients in remission at 4 years. These studies demonstrate that intensive chemotherapy can be administered to pediatric patients and young adults and that this approach to therapy produces a high remission rate with a 3 year median duration of remission.

References

Jan 1, 1978·Medical and Pediatric Oncology·H D Preisler
Sep 13, 1979·The New England Journal of Medicine·E D ThomasP L Weiden
Jan 1, 1976·The Journal of Pediatrics·P A PizzoB G Leventhal

❮ Previous
Next ❯

Citations

Feb 1, 1989·European Journal of Pediatrics·S O Lie
Feb 24, 1984·Pharmaceutisch Weekblad. Scientific Edition·R Willemze
Jan 1, 1992·International Journal of Clinical & Laboratory Research·Z A ArlinH G Chun
Mar 24, 1984·Lancet·R E MarcusD A Galton
Mar 1, 1985·Archives of Disease in Childhood·J M Chessells
Aug 1, 1988·Archives of Disease in Childhood·J M Chessells
Feb 1, 1984·European Journal of Cancer & Clinical Oncology·H D Preisler
Nov 1, 1987·European Journal of Cancer & Clinical Oncology·A M CarellaM Risso
Jun 1, 1987·Blood Reviews·H D Preisler
Dec 1, 1984·European Journal of Cancer & Clinical Oncology·A RazaH D Preisler
Mar 1, 1984·British Journal of Haematology·A M Worsley, D A Galton
Jan 1, 1988·Medical and Pediatric Oncology·L F OdomM Blake
Aug 1, 1987·European Journal of Haematology·M Beran, A R Zander
Jun 1, 1985·American Journal of Hematology·J GoldbergA J Gottlieb
Apr 1, 1991·European Journal of Haematology·A WahlinH Jonsson
Sep 1, 1984·Scandinavian Journal of Haematology·S O Lie, S H Slördahl
Mar 1, 1992·Blood Reviews·K A Foon, R P Gale

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.